Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells.
M. D. Poskus, J. McDonald, M. Laird, R. Li, K. Norcoss, I. K. Zervantonakis
This study identifies PAI1 and PLK1 as predictors of fibroblast-mediated resistance in HER2+ breast cancer and shows that targeting these proteins with lapatinib improves treatment efficacy.
bioRxiv · May 18, 2024Bioengineering